Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination of Chemotherapy With Taxol, Adriamycin, and Cytoxan (TAC), Multiple Infusions of Activated T Cells (ATC), Interleukin-2 (IL-2) and GM-CSF for High Risk Breast Cancer With and Without Her2/Neu Overexpression. (Phase I/II).

Next Previous
X
Search
Trial Profile

Combination of Chemotherapy With Taxol, Adriamycin, and Cytoxan (TAC), Multiple Infusions of Activated T Cells (ATC), Interleukin-2 (IL-2) and GM-CSF for High Risk Breast Cancer With and Without Her2/Neu Overexpression. (Phase I/II).

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Activated T cells; Cyclophosphamide; Doxorubicin; Filgrastim; Interleukin-2; Paclitaxel; Sargramostim; Taxanes
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 05 May 2015 Biomarkers information updated
    • 09 Mar 2010 Planned end date (1 Jan 2007) added as reported by ClinicalTrials.gov record.
    • 09 Mar 2010 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top